光啟技術(002625.SZ):簽訂航空超材料產品研製合同以及收到客户投產通知
格隆匯 12 月 30日丨光啟技術(002625.SZ)公佈,2020年12月29日,公司收到下屬子公司深圳光啟尖端技術有限責任公司(“光啟尖端”)通知,光啟尖端近日分別與瀋陽某客户簽訂了4108萬元的研製合同,並且收到了南昌某客户的投產通知,金額3960萬元的,兩者合計8068萬元。上述訂單不在公司已披露的超過12億元訂貨需求範圍內,屬於新增的業務訂單。
根據合同內容,光啟尖端將向瀋陽某客户提供航空超材料產品的獨家研製服務,金額4108萬元;根據投產通知的要求,光啟尖端將向南昌某客户交付航空超材料批產產品,金額3960萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.